Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

132.46 +0.05 (+0.04%)
Streaming Delayed Price Updated: 1:56 PM EDT, May 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2 3 4 5 6 7 8 9
...
46 47 Next >
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
Via Benzinga
2 Top Pharma Stocks That Just Keep Getting Better and Better
Both of these businesses are finding traction in a pair of major markets. 
Via The Motley Fool
Novo Nordisk's Wegovy Delivers: Long-Term Study Shows Sustained Weight Loss As Drugmaker Tries To Woo Insurers And Governments
The data could potentially bolster Novo's case for Wegovy as it attempts to convince insurers and governments to cover the cost of the drug. 
Via Benzinga
Novo Nordisk's Hemophilia Candidate Can Prevent Bleeding Episodes Effectively, Regardless Of Dosing Frequency
Novo Nordisk's Phase 3a trial demonstrates a significant reduction in bleeding episodes with Mim8 treatment for hemophilia A patients. Superior efficacy and safety profile revealed. 
Via Benzinga
How Viking Therapeutics Stock Could 30x
This mid-cap biopharma may one day be a titan of the industry. 
Via The Motley Fool
The Must-Watch List: 3 Stocks to Snap Up as Soon as They Hit Bargain Territory
These three companies could soon be the next bargain stocks to buy as the market adjusts to their developing situations. 
Via InvestorPlace
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
These stocks are both experts in their respective fields. 
Via The Motley Fool
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
These pharmaceutical companies are top-notch dividend growth stocks for the future. 
Via The Motley Fool
7 Stocks That Ordinary Investors Can’t Get Enough Of Right Now
While people tend to be too cool for school regarding groupthink, these popular stocks among retail investors could change perceptions. 
Via InvestorPlace
Can Weight Loss Companies Fuel Gains In Your Stock Portfolio?
Analysts predict the weight loss drug market could reach $100 billion by the end of the decade, with millions of patients potentially using these medications. However, challenges remain. 
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
The second wave of the weight loss drug stock boom is underway and investors should heed the signs the market is serving. 
Via InvestorPlace
3 Million Reasons Novo Nordisk Still Looks Like a Phenomenal Buy
This is a stock you shouldn't hesitate to buy on the dip. 
Via The Motley Fool
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy. 
Via InvestorPlace
Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) is showing decent growth, but is still valued reasonably. 
Via Chartmill
Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon
Eli Lilly stock continues to move higher after the company reported continuing momentum for its flagship GLP-1 weight loss drugs 
Via MarketBeat
'Ozempic Ftw:' Elon Musk Touts Novo Nordisk's Blockbuster Drug As Solution To Childhood Obesity Problem
This is not the first time the tech mogul has seemingly backed the blockbuster drug. Last year, Musk claimed that Ozempic was affecting food sales at Walmart. 
Via Benzinga
Eli Lilly Raised Its Outlook. Is the Stock a Buy Now?
The anti-obesity medication stock is way up, and there could be more fuel in the tank. 
Via The Motley Fool
Why Amgen Stock Zoomed Nearly 12% Higher Today
The company delivered solid quarterly results, but its discussion of an investigational drug is what really gave its shares a pop. 
Via The Motley Fool
3 Under-The-Radar Stocks That Could Be Worth Over $1 Trillion by 2030
These under-the-radar stocks have the potential to reach a $1 trillion valuation by 2030 as they gain momentum in their respective industries. 
Via InvestorPlace
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
The Nasdaq regained its 50-day line Friday. The other indexes hit resistance. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Wage Growth Slows – Stock Market Celebrates, Five Real Reasons Apple Is Running Up
To gain an edge, this is what you need to know today. 
Via Benzinga
AMGN Stock Alert: Is Amgen the Next Hot Weight-Loss Drug Company?
Amgen (AMGN) stock is soaring after the company's CEO said he was "very encouraged" by interim data for Amgen's new weight-loss drug. 
Via InvestorPlace
The Big Split: 3 Stock Spinoffs Are Coming. Should You Buy?
Stock spinoffs can unlock shareholder value but management sometimes uses them to get rid of unwanted, slow-growing businesses. 
Via InvestorPlace
This Is a Huge Sigh of Relief for Novo Nordisk Investors
The path is clear for even more growth from Novo Nordisk's top two drugs, Ozempic and Wegovy. 
Via The Motley Fool
Weigh Loss Competition Heats Up In Britain, Online Pharmacies Slash Prices for Wegovy and Mounjaro
Reduced prices on Wegovy and Mounjaro at British pharmacies amid growing competition. Simple Online Pharmacy slashes Mounjaro starter doses to £149 from £179, catering to high demand. 
Via Benzinga
Novo Nordisk (NVO) Q1 2024 Earnings Call Transcript
NVO earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
NVO Stock Earnings: Novo Nordisk Beats EPS, Beats Revenue for Q1 2024
NVO stock results show that Novo Nordisk beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Novo Nordisk Dips As Q1 Wegovy Sales Double, But Miss Target
Novo Nordisk stock came under mild selling pressure early Thursday, after the company reported Q1 results and lifted guidance. 
Via Investor's Business Daily
Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition
The Danish pharmaceutical company is now shipping more introductory doses of Wegovy to the U.S., as it grapples with supply constraints and competition from Eli Lilly. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
46 47 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.